
Biotechnology & ‘Fog of Valuation’ savant
| Platform | Pricing | Freemium | Publishes | Daily | |
|---|---|---|---|---|---|
| Issues | 253 | Founded | 2 years ago | Last Issue | 4 days ago |
| Active | |||||

Watch now (32 mins) | United Therapeutics, Liquidia, and the economics of competition when intellectual property, market expansion, and patient access intersect.
Update — October 14, 2026: This morning, United Therapeutics (UTHR) and Liqui...
Every autumn, the biotechnology industry enters one of its busiest periods. Earnings reports, medical conferences, investor meetings, and management presentations begin arriving in rapid succession. For investors, the challenge is not simpl...
Inspired by Mark Schoenebaum, we explore biotechnology's evolving conversations, the promise of AI-assisted research, and why analytical discipline matters as much as discovery.
I. A Lesson from Mark Schoenebaum
MYQORZO challenges Bristol Myers Squibb’s CAMZYOS as cardiac myosin inhibitors gain traction. We examine market expansion, competitive differentiation, and the expectations facing investors.
Cytokinetics (NASDAQ: CYTK) has entered a new ch...
September was a busy month at the Biotech Capital Compass.
We published 15 pieces across newsletters, Tape Checks, Video Companions, Video Recaps, and conversations. But looking back, the number of publications may be the least interesting...
Subscribers, engagement, traffic and sponsorship for The Biotech Capital Compass.
| Subscribers | Engagement | 71 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
The writers behind this newsletter.
Biotech Capital Compass breaks down complex biotech stories into valuation, risk, and narrative frameworks investors can use. Written by Hartaj Singh, a biotech analyst focused on translating innovation into investment reality.
You can find recent issues that have been published by The Biotech Capital Compass on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
To see how many people subscribe to The Biotech Capital Compass, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
Newsletter advertising can be extremely effective when it's done right. Before you pitch The Biotech Capital Compass as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The Biotech Capital Compass using the contact information provided and ask for a copy of their media kit.
Scroll up to where it says Related Newsletters to see other publications like The Biotech Capital Compass. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.